comparemela.com
Home
Live Updates
BI 764532 Yields Promising Safety and Efficacy Results in DLL3+ SCLC and NEC : comparemela.com
BI 764532 Yields Promising Safety and Efficacy Results in DLL3+ SCLC and NEC
Martin Wermke, MD, discusses why the novel T-cell engager BI 764532 may serve as a promising treatment option targeting DLL3 in small cell lung cancer and neuroendocrine carcinomas .
Related Keywords
Dresden ,
Sachsen ,
Germany ,
Martin Wermke ,
University Hospital Carl Gustav Carus ,
Early Clinical Trial Unit ,
National Center ,
Tumor Diseases Dresden ,
Developmental Therapeutics ,
Dll3 ,
Bi 764532 ,
Nsclc ,
Dll3 Positive Small Cell Lung Cancer ,
Neuroendocrine Carcinomas ,
comparemela.com © 2020. All Rights Reserved.